Allergan Moves Into Busy CGRP Class By Buying Merck’s Oral Drugs
This article was originally published in The Pink Sheet Daily
Allergan agreed to pay $250 million up front for global rights two investigational oral CGRP antagonists in early clinical development for acute treatment and prevention of migraine. Several rivals are racing to develop injectable CGRP antibodies.
Register for our free email digests: